The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

ILLUMINATE consortium

ILLUMINATE - Increasing lutetium production while leveraging metabolic imaging to enhance theranostics effectiveness, is a new international consortium of academic and industrial leaders, with the aim to demonstrate the unique value of recently developed Metabolic Magnetic Resonance Imaging (MeMRI) visualizing chemical processes in the body to significantly improve effective application of theranostics – an approach combining diagnosis, treatment, and continuous follow up of a condition.

About

The collaborative research program aims to demonstrate the unique value of recently developed Metabolic Magnetic Resonance Imaging (MeMRI) visualizing chemical processes in the body to significantly improve effective application of theranostics – an approach combining diagnosis, treatment, and continuous follow up of a condition. ILLUMINATE will provide the first clinical translation of MeMRI, with application to castrate resistant metastatic prostate cancer. This will pave the way for future expansion of the technology for use in earlier cancer stages and in other cancer types.

ILLUMINATE is a collaborative research program which aims to demonstrate the unique value of Metabolic Magnetic Resonance Imaging (MeMRI), used to visualize chemical processes in the body, to significantly improve effective application of theranostics - an approach combining diagnosis, treatment, and continuous follow up of a condition. ILLUMINATE will provide the first clinical translation of MeMRI, with application to castrate resistant metastatic prostate cancer. This will pave the way for future expansion of the technology for use in earlier cancer stages and in other cancer types. 

In parallel, ILLUMINATE seeks to increase the overall availability of lutetium - a highly promising targeted radioligand therapy recently approved for metastasized prostate cancer, and develop more sustainable production methods for it. 

ILLUMINATE is a four-and-a-half-year public-private partnership, funded by the Innovative Health Initiative (IHI). 

Partners

Among ILLUMINATE’s partners are MedTech companies, research institutes, university hospitals and small- and medium-sized enterprises. 

ILLUMINATE’s partners are: UMC Utrecht, Euro-Bioimaging ERIC, Philips Medical Systems Nederland BV, Philips Gmbh Innovative Technologies, Synlab Sdn Spa, Consiglio Nazionale Delle Ricerche, University of Turin, Bracco Imaging Spa, Tesla Dynamic Coils BV, Wavetronica BV, Lund University, Nuclear Research & Consultancy Group, Amsterdam UMC, University Hospital Essen, Lygature. 

The consortium is coordinated by UMC Utrecht, together with NRG PALLAS as a project lead. 

Acknowledgement of support 

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101172722. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe.

Logotyp, blå bakgrund med vita strålar.

More information